Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 01:58pm CET

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Stocks mentioned in the article
ChangeLast1st jan.
SANOFI 0.25% 65.05 Real-time Quote.-9.69%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
06:46pSANOFI : Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition..
AQ
04:10pImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer
AQ
12:30pSANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
10:07aSANOFI : Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Bi..
GL
10:07aSANOFI : Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Bi..
AQ
09:36aSANOFI : extends its `Empowering Life` corporate rebrand with overhaul of digita..
AQ
02/21SANOFI : forms new alliance with CRN Greater Manchester
AQ
02/20SANOFI : anofi diverting attention from real issues' -- Gordon
AQ
02/20SANOFI : firm against full refund, financial aid to Dengvaxia recipients
AQ
02/20SANOFI : Manchester CRN gets Premier Site status from Sanofi
AQ
More news
News from SeekingAlpha
06:50aHSR waiting period over for Sanofi's purchase of Bioverativ 
02/22Tracking Jeffrey Ubben's ValueAct Portfolio - Q4 2017 Update 
02/22ACETO : Collapsing Generic Drug Pricing Brings Risk Of Covenant Violations 
02/21ROTY EDITION 1 VOLUME 81 : We Have A Launch Date! 
02/20BIOTECHS : Still Well Placed For More Gains 
Financials (€)
Sales 2018 35 367 M
EBIT 2018 8 919 M
Net income 2018 5 324 M
Debt 2018 11 557 M
Yield 2018 4,71%
P/E ratio 2018 15,07
P/E ratio 2019 13,70
EV / Sales 2018 2,64x
EV / Sales 2019 2,47x
Capitalization 81 965 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 83,0 €
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-9.69%100 822
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.27%213 155
ROCHE HOLDING LTD.-9.41%207 327
MERCK AND COMPANY-3.06%148 618